Hyperpolarized 129Xe MRI: Inhalation of hyperpolarized 129Xe gas followed by breath-hold MRI for ventilation imaging.
Tc-99m Technegas Ventilation Imaging: Inhalation of Tc-99m-labeled carbon aerosol (Technegas) followed by SPECT imaging to assess lung ventilation.
Study summary
The goal of this observational study is to better understand how asthma affects the lungs in young adults (ages 17-35) with mild asthma. The main questions it aims to answer are:
* Can advanced imaging detect abnormal airway function in people with mild asthma?
* Do changes in ventilation imaging correlate with asthma symptoms or quality of life? Researchers will compare hyperpolarized xenon-129 MRI and Technegas (Tc-99m) imaging to see if these techniques reveal more detailed lung abnormalities than standard lung function tests.
Participants will:
* Complete a single 2-hour visit
* Undergo two types of lung imaging: Hyperpolarized xenon-129 MRI (to visualize how air moves in the lungs), Technegas (Tc-99m) imaging (to assess airflow using nuclear medicine)
* Perform spirometry and other breathing tests
* Answer questionnaires about asthma symptoms and quality of life This study is designed to improve our understanding of subtle changes in lung function that may not be detected by standard tests in people with mild asthma. The findings may lead to better diagnostic tools and more personalized treatment strategies in the future.
Eligibility
Sex
ALL
Min age
17 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
1. Participant diagnosed with mild (GINA1) asthma by physician
2. Participant understands study procedures and is willing to participate in the study as indicated by the participant's signature
3. Provision of written, informed consent prior to any study specific procedures
4. Males and females 17 to 35 years of age
5. Women of childbearing potential (after menarche) must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. Examples of effective birth control include:
1. True sexual abstinence
2. A vasectomized sexual partner
3. Implanon®
4. Female sterilization by tubal occlusion
5. Effective intrauterine device (IUD)/levonogestrel intrauterine system (IUS)
6. Depo-Provera™ injections
7. Oral contraceptive
8. Evra Patch™
9. Nuvaring™
Exclusion Criteria:
Participants fulfilling any of the following criteria are not eligible for inclusion in this study:
1. Participant has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist)
2. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, CT, or Tc99CImaging, such as severe claustrophobia
3. Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit
4. Participant is unable to perform spirometry or plethysmography maneuvers
5. Participant is unable to perform MRI and CT breath-hold maneuvers
Primary outcome measure(s)
Measure 129Xe and Tc99C Imaging ventilation defects qualitatively and quantitatively in participants diagnosed and treated as "mild" asthma. — 1 baseline visit for pre- and post-bronchodilator imaging assessments Ventilation defects will be assessed using 129Xe MRI and Tc-99m Technegas SPECT imaging. Measurements will include ventilation defect percentage (VDP) and visual scoring to evaluate ventilation abnormalities in participants with mild asthma.
Trial sites (1)
Facility
City
Region
Status
Robarts Research Institute; The University of Western Ontario
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.